FairJourney Biologics completed the acquisition of the South San Francisco facility from Charles River Laboratories International.

FairJourney Biologics, a provider of antibody discovery and development services, completed the acquisition of the South San Francisco facility from Charles River Laboratories International, a pharmaceutical company. Financial terms were not disclosed. “We’re pleased to announce this strategic acquisition that will bring the exceptional team at Charles River’s South San Francisco site, as well as their cutting-edge technologies, into FairJourney. By combining our expertise, we not only strengthen our portfolio with powerful solutions such as the SuperHuman Libraries, but also enhance our ability to deliver innovative solutions to our partners. Working together, we can push the boundaries of antibody discovery and set new industry standards,” António Parada, FairJourney Biologics CEO.